AR128514A1 - Formulación líquida de toxina botulínica y su uso - Google Patents
Formulación líquida de toxina botulínica y su usoInfo
- Publication number
- AR128514A1 AR128514A1 ARP230100336A ARP230100336A AR128514A1 AR 128514 A1 AR128514 A1 AR 128514A1 AR P230100336 A ARP230100336 A AR P230100336A AR P230100336 A ARP230100336 A AR P230100336A AR 128514 A1 AR128514 A1 AR 128514A1
- Authority
- AR
- Argentina
- Prior art keywords
- liquid formulation
- serum albumin
- human serum
- botulinum toxin
- tryptophan
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title abstract 12
- 108030001720 Bontoxilysin Proteins 0.000 title abstract 4
- 229940053031 botulinum toxin Drugs 0.000 title abstract 4
- 102000008100 Human Serum Albumin Human genes 0.000 abstract 5
- 108091006905 Human Serum Albumin Proteins 0.000 abstract 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 2
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 abstract 2
- DZTHIGRZJZPRDV-UHFFFAOYSA-N Nalpha-Acetyltryptophan Natural products C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-N 0.000 abstract 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 2
- 239000002738 chelating agent Substances 0.000 abstract 2
- 229910001447 ferric ion Inorganic materials 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229940116191 n-acetyltryptophan Drugs 0.000 abstract 2
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 abstract 1
- -1 Fe3+ ions Chemical class 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000012929 tonicity agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención está relacionada con una formulación líquida que comprende (i) toxina botulínica, (ii) albúmina de suero humano (ASH), y opcionalmente (iii) un agente de tonicidad y/o (iv) un agente de tamponamiento. En un aspecto, la formulación líquida está caracterizada por una concentración muy baja de iones férricos. En otro aspecto, la formulación líquida se caracteriza por la ausencia o la muy baja concentración de triptófano y/o N-acetil-triptófano. De acuerdo con la presente invención, la formulación líquida se puede preparar mediante un método que comprende los pasos de poner en contacto albúmina de suero humano con un agente quelante para obtener una mezcla y remover el agente quelante de la mezcla. Asimismo, la presente invención está relacionada con el uso de la formulación líquida para el tratamiento de indicaciones terapéuticas y afecciones cosméticas. Reivindicación 1: Una formulación líquida, que comprende (i) toxina botulínica y (ii) albúmina de suero humano, donde la formulación líquida contiene iones de Fe³⁺ en una concentración menor que 1 mM, preferentemente menor que 500 nM, y más preferentemente menor que 250 nM. Reivindicación 2: Una formulación líquida, que comprende (i) toxina botulínica y (ii) albúmina de suero humano, donde la formulación líquida no contiene o no contiene más de 50 mM de triptófano y N-acetil-triptófano. Reivindicación 6: La formulación líquida de cualquiera de las reivindicaciones 1 a 5, donde la albúmina de suero humano está presente en la formulación líquida en una cantidad de 0,001 - 1,00% p/v.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22156843 | 2022-02-15 | ||
| EP22183172 | 2022-07-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128514A1 true AR128514A1 (es) | 2024-05-15 |
Family
ID=85202119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100336A AR128514A1 (es) | 2022-02-15 | 2023-02-14 | Formulación líquida de toxina botulínica y su uso |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR128514A1 (es) |
| TW (1) | TW202348248A (es) |
| WO (1) | WO2023156389A1 (es) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060269575A1 (en) * | 2000-02-08 | 2006-11-30 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions formulated with recombinant albumin |
| US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
| JP2006045173A (ja) * | 2004-08-09 | 2006-02-16 | Hidetoshi Tsuchida | 表面修飾血清アルブミン−金属ポルフィリン複合体、およびそれを含有する酸素輸液 |
| CA2715033C (en) | 2008-03-14 | 2014-11-25 | Allergan, Inc. | Immuno-based botulinum toxin serotype a activity assays |
| US8591884B2 (en) * | 2009-06-24 | 2013-11-26 | CNSS IP Holdings, Inc | Compositions and methods for enhancing metal ion dependent drug therapies |
| SI2761065T1 (en) | 2011-09-29 | 2018-02-28 | Cellsnap, Llc | Ingredients and procedures for toxicity testing |
| MX360513B (es) | 2013-06-28 | 2018-11-07 | Merz Pharma Gmbh & Co Kgaa | Medios y metodos para la determinacion de la actividad biologica de polipeptidos de neurotoxina en celulas. |
| US20190183988A1 (en) | 2016-05-27 | 2019-06-20 | Ipsen Biopharm Limited | Neurotoxin formulation |
-
2023
- 2023-02-14 AR ARP230100336A patent/AR128514A1/es unknown
- 2023-02-14 TW TW112105172A patent/TW202348248A/zh unknown
- 2023-02-14 WO PCT/EP2023/053647 patent/WO2023156389A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202348248A (zh) | 2023-12-16 |
| WO2023156389A1 (en) | 2023-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bilodeau et al. | Reactive oxygen species-mediated loss of bovine sperm motility in egg yolk Tris extender: protection by pyruvate, metal chelators and bovine liver or oviductal fluid catalase | |
| Lowell et al. | In vitro evaluation of endothelial and smooth muscle function of primary varicose veins | |
| Latchoumycandane et al. | Chronic ethanol ingestion induces oxidative kidney injury through taurine-inhibitable inflammation | |
| Burgalassi et al. | Cytotoxicity of potential ocular permeation enhancers evaluated on rabbit and human corneal epithelial cell lines | |
| Muguerza et al. | Antifibrogenic effect in vivo of low doses of insulin-like growth factor-I in cirrhotic rats | |
| Kligman | Corneobiology and Corneotherapy-a final chapter. | |
| ECSP024352A (es) | Nueva composicion farmaceutica | |
| JP7228531B2 (ja) | 皮膚バリア組成物 | |
| Yu et al. | Endogenous superoxide dismutase activation by oral administration of riboflavin reduces abdominal aortic aneurysm formation in rats | |
| BRPI0907970A8 (pt) | composição para tratamento dos cabelos ou pelos e método para aumentar o diâmetro dos cabelos ou pelos | |
| Fteita et al. | Does estradiol have an impact on the dipeptidyl peptidase IV enzyme activity of the Prevotella intermedia group bacteria? | |
| AR128514A1 (es) | Formulación líquida de toxina botulínica y su uso | |
| BR112022013547A2 (pt) | Métodos para potencializar a farmacocinética, para aumentar a concentração plasmática e a vigília ou diminuir a sonolência excessiva, e, composição | |
| El Ayadi et al. | Metal chelation attenuates oxidative stress, inflammation, and vertical burn progression in a porcine brass comb burn model | |
| AR054435A1 (es) | Agente para profilaxis o terapia contra la depresion o desorden de ansiedad | |
| Gasset et al. | Hydrogen peroxide sterilization of hydrophilic contact lenses | |
| JP2011111441A (ja) | 非イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| TWI724210B (zh) | 一種具抗老化、美白、抗過敏及細胞修護之龍眼花萃取物 | |
| Falavigna et al. | Improving sperm viability after spinal cord injury using hyperbaric therapy | |
| JP5650864B2 (ja) | 非イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| DE59002738D1 (de) | Kombinationspräparate enthaltend Chloramphenicol, Gentamicin und Nystatin als aktive Wirkstoffe zur topischen Behandlung entzündlicher Hauterkrankungen. | |
| Hashimoto et al. | Effects of nonsteroidal anti-inflammatory drugs on experimental allergic conjunctivitis in guinea pigs | |
| AR128515A1 (es) | Formulación de toxina botulínica líquida y su uso | |
| Wozniak et al. | Efficacy of Fractional CO2 Laser Treatment for Genitourinary Syndrome of Menopause in Short-Term Evaluation—Preliminary Study. Biomedicines 2023, 11, 1304 | |
| JPH0748595A (ja) | コンタクトレンズ用溶剤 |